Pui K. Chan

NUCLEOPHOSMIN/B23 (NPM) OLIGOMER IS A MAJOR AND STABLE ENTITY IN HELA CELLS

HeLa cell extract was separated by 7% polyacrylamide gel electrophoresis without SDS and subsequently stained with anti-nucleophosmin/B23 (NPM) antibody in a Western blot analysis. Two immunobands were obtained. The major band with a slower electromobility (RF = 0.23) is the NPM oligomer, while the fast-moving minor band is the monomer (RF = 0.56). The oligomer constitutes about 95% of total NPM. The oligomer sedimented faster (10 s) than the monomer in sucrose density gradient centrifugation. Three oligomer bands were identified. NPM oligomer is not affected by treatments with DNase. RNase, 10 mM EDTA, 1 M NaCl, and lyophilization. However, 3 M urea causes reversible dissociation of NPM oligomer into monomer. The level of NPM oligomer remains unchanged in HeLa cells after treatment with the cytotoxic agents, actinomycin D, toyocamycin and camptothecin. These results indicate that NPM oligomer is the major and stable NPM entity in HeLa cells.

Characterization and cellular localization of nucleophosmin/B23 in HeLA cells treated with selected cytotoxic agents (studies of B23-translocation mechanism)

Previous studies indicated that nucleophosmin/B23, an abundant nucleolar phosphoprotein, accumulated in the nucleoplasm (B23-translocation) of cells after exposure to selected cytotoxic drugs. Attempts were made to understand the B23-translocation mechanism. This paper reports that: (1) B23-translocation is a reversible process. Upon removal of camptothecin, which induced B23-translocation in HeLa cells, nucleophosmin/B23 relocalized into nucleoli within 2 h. Relocation occurs in the presence of cycloheximide which inhibits new protein synthesis. There is no reduction or degradation of nucleophosmin/B23 detected during drug treatments. Nucleophosmin/B23 has a half-life of 18-20 h. Taken together, these results indicate that B23-translocation is a reversible process. Drug treatment causes redistribution of nucleophosmin/B23 in nucleoplasm. (2) Inhibition of RNA synthesis does not cause the B23-translocation. Over 80% of RNA synthesis was inhibited in HeLa cells by treatment with actinomycin D, camptothecin, and methotrexate. While actinomycin D and camptothecin cause B23-translocation in all cells, 40% of methotrexate-treated cells remain untranslocated. (3) There is no significant change of phosphorylation in nucleophosmin/B23 during drug treatment. An identical oligomeric cross-linkage pattern was obtained in drug-treated cells. (4) HeLa cells treated with B23-translocation effective drugs have small and round nucleoli while control cells have large and irregular-shaped nucleoli.

A study of correlation between NPM-translocation and apoptosis in cells induced by daunomycin

Human leukemia K562 and HeLa cells were treated with daunomycin (DA) for 1-4 hr. With the indirect immunofluorescence technique, we observed that the nucleolar protein nucleophosmin/B23 (NPM) shifted its location from the nucleolus to the nucleoplasm (NPM-translocation). The degree of NPM-translocation was determined by the relative immunofluorescent intensity in the nucleoli vs the nucleoplasm (defined as localization index, LI). We found that NPM-translocation, as determined by the decrease of LI, correlates with cytotoxicity. The degrees of NPM-translocation, chromatin condensation, and DNA fragmentation in HeLa cells were determined after treatment with 0.1, 0.5 and 1 microg/mL DA for 1 hr. We found that NPM-translocation (LI < 2.5) was observed in cells during the treatment with 0.5 and 1 but not with 0.1 microg/mL DA. Also, cells treated with 1 microg/mL remained in an NPM-translocated state for a longer time (5-6 hr) than those cells treated with 0.5 microg/mL (1-2 hr). Cells treated with 0.5 and 1 microg/mL DA showed increased levels of chromatin condensation beginning at 5 hr after the drug treatment. The number of cells with condensed chromatin increased with both time and drug concentration. No cells with condensed chromatin were observed in samples treated with 0.1 microg/mL DA, which also showed no significant NPM-translocation. Similar results were observed for induction of DNA fragmentation. We found that the drug concentration required for induction of DNA fragmentation and chromatin condensation coincided with the drug concentration required for NPM-translocation. Taken together, these results indicate that NPM-translocation correlates with apoptosis induced by daunomycin.

Identification of a long stretch of homopurine.homopyrimidine sequence in a cluster of retroposons in the human genome.

A cluster of nine retroposons of four different types in a 6221 base EcoRI DNA fragment was isolated from a human fetal liver genomic library using a human nucleophosmin (B23) cDNA as a probe. These retroposons are: (1) a solitary HERV-K long terminal repeat upstream from; (2) a nucleophosmin processed pseudogene; (3) six Alu repeated sequences interspersed in both directions; and (4) a truncated Kpn repeated sequence integrated by an Alu monomer and the HERV-K long terminal repeat. Sequence analysis shows that the nucleophosmin pseudogene contains a long stretch (135 base-pairs) of homopurine.homopyrimidine (Pur.Pyr) sequence. S1 and P1 nuclease digestion indicated that this sequence was able to adopt a non-B-DNA triplex structure under either acidic or neutral conditions. This finding is the first example of the association of a potential DNA triplex structure with a cluster of retroposons.

Studies of actinomycin D induced B23-translocation in P388D1 cells implanted in DBA/2 mice

Nucleophosmin/B23 is a nucleolar phosphoprotein which redistributes from nucleoli to nucleoplasm (B23-translocation) when cells are exposed to certain anticancer drugs, particularly intercalators. The B23-translocation assay has been demonstrated in cell culture to correlate with drug effects and to detect drug-resistant cells. We now report the effect of actinomycin D on B23-translocation in P388D1 cells implanted in DBA/2 mice. B23-translocation was observed in cells after actinomycin D treatment in a dosage- and time-dependent manner. Translocation could be observed within 30 min after drug treatment. Complete B23-translocation with at least 1-day duration was achieved by a single injection of 0.25 mg/kg. Reduced dosages produced partial B23-translocation with shorter durations. These results indicate that B23-translocation may be useful in monitoring drug effects in animals.